PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine

References

• Hansen M, Met O, Svane IM, Andersen MH. Cellular based cancer vaccines: type 1 polarization of dendritic cells. Curr Med Chem 2012; 19:4239-46; PMID:22834814; http://dx.doi.org/10.2174/092986712802884213
   PubMed Web of Science ®Google Scholar
• Tamura H, Dong H, Zhu G, Sica GL, Flies DB, Tamada K, Chen L. B7-H1 co-stimulation preferentially enhances CD28-independent T-helper cell function. Blood 2001; 97:1809-16; PMID:11238124; http://dx.doi.org/10.1182/blood.V97.6.1809
   PubMed Web of Science ®Google Scholar
• Tewalt EF, Cohen JN, Rouhani SJ, Guidi CJ, Qiao H, Fahl SP, Conaway MR, Bender TP, Tung KS, Vella AT et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of co-stimulation leading to high-level PD-1 expression on CD8 T cells. Blood 2012; 120:4772-82; PMID:22993390; http://dx.doi.org/10.1182/blood-2012-04-427013
   PubMed Web of Science ®Google Scholar
• Seo SK, Seo DI, Park WS, Jung WK, Lee DS, Park SG, Choi JS, Kang MS, Choi YH, Choi I et al. Attenuation of IFN-gamma-induced B7-H1 expression by 15-deoxy-delta(12,14)-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway. Life Sci 2014; 112:82-9; PMID:25072357; http://dx.doi.org/10.1016/j.lfs.2014.07.021
   PubMed Web of Science ®Google Scholar
• Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5:1365-69; PMID:10581077; http://dx.doi.org/10.1038/70932
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 2014; 28:1784-92; PMID:24691076; http://dx.doi.org/10.1038/leu.2014.108
   PubMed Web of Science ®Google Scholar
• Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 2009; 23:375-82; PMID:18830259; http://dx.doi.org/10.1038/leu.2008.272
   PubMed Web of Science ®Google Scholar
• Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L et al. Co-stimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004; 101:17174-79; PMID:15569934; http://dx.doi.org/10.1073/pnas.0406351101
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007; 104:3360-5; PMID:17360651; http://dx.doi.org/10.1073/pnas.0611533104
   PubMed Web of Science ®Google Scholar
• Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13:2151-7; PMID:17404099; http://dx.doi.org/10.1158/1078-0432.CCR-06-2746
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of Anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-53; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Munir S, Andersen GH, Met O, Donia M, Frosig TM, Larsen SK, Klausen TW, Svane IM, Andersen MH. HLA-restricted cytotoxic T cells that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res 2013; 73:1674-776; PMID:23328583; http://dx.doi.org/10.1158/0008-5472.CAN-12-3507
   Web of Science ®Google Scholar
• Munir S, Andersen GH, Woetmann A, Odum N, Becker JC, Andersen MH. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 2013; 27:2251-3; PMID:23660624; http://dx.doi.org/10.1038/leu.2013.118
   PubMed Web of Science ®Google Scholar
• Andersen MH, Sorensen RB, Brimnes MK, Svane IM, Becker JC, thor Straten P. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest 2009; 119:2245-56; PMID:19662679; http://dx.doi.org/10.1172/JCI38739
   PubMed Web of Science ®Google Scholar
• Ahmad SM, Larsen SK, Svane IM, Andersen MH. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia 2014; 28:236-8; PMID:24091833; http://dx.doi.org/10.1038/leu.2013.261
   PubMed Web of Science ®Google Scholar
• Munir S, Andersen GH, Svane IM, Andersen MH. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells. Oncoimmunology 2013; 2:e23991; PMID:23734334; http://dx.doi.org/10.4161/onci.23991
   PubMed Web of Science ®Google Scholar
• Borch TH, Donia M, Andersen MH, Svane IM. Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discov Today 2015; 20:1127-34; PMID:26189934; http://dx.doi.org/10.1016/j.drudis.2015.07.003
   PubMed Web of Science ®Google Scholar
• Andersen MH. Immune regulation by self-recognition: novel possibilities for anticancer immunotherapy. J Natl Cancer Inst 2015; 107:154; PMID:26063792; http://dx.doi.org/10.1093/jnci/djv154
   Google Scholar
• Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, Shah B, Chang SH, Schluns KS, Watowich SS et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29:44-56; PMID:18585065; http://dx.doi.org/10.1016/j.immuni.2008.05.007
   PubMed Web of Science ®Google Scholar
• Chen Z, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008; 41:87-102; PMID:18172584; http://dx.doi.org/10.1007/s12026-007-8014-9
   PubMed Web of Science ®Google Scholar
• Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10:248-56; PMID:20336152; http://dx.doi.org/10.1038/nri2742
   PubMed Web of Science ®Google Scholar
• Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, Thor SP, Andersen MH, Pedersen AE, Claesson MH, Lorentzen T, Johansen JS et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008; 31:771-80; PMID:18779742; http://dx.doi.org/10.1097/CJI.0b013e3181833818
   PubMed Web of Science ®Google Scholar
• Rammensee HG, Falk K, Roetzschke O. MHC molecules as peptide receptors. Curr Biol 1995; 5:35-44; PMID:7697344; http://dx.doi.org/10.1016/S0960-9822(95)00011-X
   PubMed Web of Science ®Google Scholar